Russell Investments Group Ltd. Raises Stock Holdings in Chimerix Inc (NASDAQ:CMRX)

Russell Investments Group Ltd. increased its stake in shares of Chimerix Inc (NASDAQ:CMRX) by 70.8% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 129,491 shares of the biopharmaceutical company’s stock after purchasing an additional 53,669 shares during the quarter. Russell Investments Group Ltd. owned approximately 0.21% of Chimerix worth $305,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Acadian Asset Management LLC lifted its stake in shares of Chimerix by 15.4% during the 2nd quarter. Acadian Asset Management LLC now owns 557,029 shares of the biopharmaceutical company’s stock worth $2,407,000 after purchasing an additional 74,472 shares during the last quarter. Bank of New York Mellon Corp raised its stake in Chimerix by 13.8% in the second quarter. Bank of New York Mellon Corp now owns 212,353 shares of the biopharmaceutical company’s stock valued at $917,000 after buying an additional 25,794 shares during the last quarter. Vanguard Group Inc. raised its stake in Chimerix by 35.7% in the second quarter. Vanguard Group Inc. now owns 1,956,956 shares of the biopharmaceutical company’s stock valued at $8,454,000 after buying an additional 514,727 shares during the last quarter. BlackRock Inc. raised its stake in Chimerix by 5.3% in the second quarter. BlackRock Inc. now owns 3,386,633 shares of the biopharmaceutical company’s stock valued at $14,630,000 after buying an additional 169,550 shares during the last quarter. Finally, Meeder Asset Management Inc. raised its stake in Chimerix by 289.4% in the third quarter. Meeder Asset Management Inc. now owns 25,269 shares of the biopharmaceutical company’s stock valued at $60,000 after buying an additional 18,779 shares during the last quarter. Hedge funds and other institutional investors own 57.29% of the company’s stock.

Chimerix stock opened at $2.20 on Monday. The firm has a market cap of $135.04 million, a price-to-earnings ratio of -1.54 and a beta of 1.46. Chimerix Inc has a 52 week low of $1.25 and a 52 week high of $4.40. The business’s 50-day moving average price is $1.67 and its 200 day moving average price is $2.70.

Chimerix (NASDAQ:CMRX) last posted its earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.22) by $0.07. The firm had revenue of $1.96 million for the quarter, compared to analyst estimates of $1.30 million. Chimerix had a negative return on equity of 38.75% and a negative net margin of 1,162.96%. On average, sell-side analysts anticipate that Chimerix Inc will post -1.01 earnings per share for the current fiscal year.

In other Chimerix news, Director Fred A. Middleton acquired 30,000 shares of the company’s stock in a transaction on Wednesday, November 13th. The shares were bought at an average cost of $1.82 per share, with a total value of $54,600.00. Following the completion of the acquisition, the director now owns 117,523 shares in the company, valued at $213,891.86. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Michael T. Andriole acquired 100,000 shares of the company’s stock in a transaction on Wednesday, November 6th. The stock was acquired at an average cost of $1.56 per share, for a total transaction of $156,000.00. Following the completion of the acquisition, the insider now owns 100,000 shares of the company’s stock, valued at approximately $156,000. The disclosure for this purchase can be found here. Over the last ninety days, insiders have purchased 160,000 shares of company stock worth $259,600. 9.40% of the stock is owned by corporate insiders.

Separately, Zacks Investment Research upgraded Chimerix from a “hold” rating to a “buy” rating and set a $1.75 price objective for the company in a research note on Friday, November 8th. Three research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Chimerix currently has an average rating of “Hold” and a consensus target price of $3.44.

Chimerix Company Profile

Chimerix, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines that address unmet medical needs in the United States. The company's lead product candidate is brincidofovir, an investigational nucleoside analog for the prevention of viral infections in hematopoietic or stem cell transplant recipients (HCT), as well as for the treatment of adenovirus infection and disease, smallpox, and BK virus infection in kidney and HCT transplant recipients.

See Also: What is Liquidity?

Want to see what other hedge funds are holding CMRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chimerix Inc (NASDAQ:CMRX).

Institutional Ownership by Quarter for Chimerix (NASDAQ:CMRX)

Receive News & Ratings for Chimerix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix and related companies with MarketBeat.com's FREE daily email newsletter.